Zevra Therapeutics Inc. (ZVRA) — Cash Flow-to-Debt Ratio
Zevra Therapeutics Inc. (ZVRA) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of $4.71 Million could theoretically repay 0% of its total liabilities ($136.95 Million) in one year. Explore Zevra Therapeutics Inc. (ZVRA) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zevra Therapeutics Inc. Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Zevra Therapeutics Inc. across 13 annual periods. Also explore ZVRA total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Zevra Therapeutics Inc. (2012–2024)
Year-by-year debt coverage analysis for Zevra Therapeutics Inc.. For market capitalisation and broader financial context, see Zevra Therapeutics Inc. market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.50x | $-69.67 Million | $138.46 Million | ▼ -65.7% |
| 2023 | -0.30x | $-33.53 Million | $110.46 Million | ▲ +34.8% |
| 2022 | -0.47x | $-18.72 Million | $40.22 Million | ▼ -126.0% |
| 2021 | 1.79x | $10.44 Million | $5.82 Million | ▲ +7276.5% |
| 2020 | -0.02x | $-1.94 Million | $77.62 Million | ▲ +91.1% |
| 2019 | -0.28x | $-23.74 Million | $84.96 Million | ▲ +51.9% |
| 2018 | -0.58x | $-54.20 Million | $93.31 Million | ▼ -93.0% |
| 2017 | -0.30x | $-33.10 Million | $109.97 Million | ▼ -4.7% |
| 2016 | -0.29x | $-29.77 Million | $103.58 Million | ▲ +6.6% |
| 2015 | -0.31x | $-20.27 Million | $65.84 Million | ▲ +20.3% |
| 2014 | -0.39x | $-14.67 Million | $38.02 Million | ▼ -138.2% |
| 2013 | -0.16x | $-4.33 Million | $26.70 Million | ▲ +87.0% |
| 2012 | -1.25x | $-4.43 Million | $3.56 Million | — |